vs
Side-by-side financial comparison of ACHIEVE LIFE SCIENCES, INC. (ACHV) and BIOMERICA INC (BMRA). Click either name above to swap in a different company.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $749.0K | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $1.0M |
| Q4 25 | — | $-1.3M | ||
| Q3 25 | — | $2.0K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-950.0K | ||
| Q3 24 | — | $-1.3M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | 4.2% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | -33.0% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 26.7% | ||
| Q3 24 | — | 16.0% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | -14.7% |
| Q4 25 | — | -113.5% | ||
| Q3 25 | — | -81.0% | ||
| Q2 25 | — | -209.1% | ||
| Q1 25 | — | -108.1% | ||
| Q4 24 | — | -60.7% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | — | -136.6% | ||
| Q1 24 | — | -196.7% |
| Q4 25 | — | -109.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | -206.1% | ||
| Q1 25 | — | -103.9% | ||
| Q4 24 | — | -58.1% | ||
| Q3 24 | — | -72.8% | ||
| Q2 24 | — | -127.1% | ||
| Q1 24 | — | -188.6% |
| Q4 25 | — | $-0.45 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $-0.99 | ||
| Q1 25 | — | $-0.48 | ||
| Q4 24 | — | $-0.06 | ||
| Q3 24 | — | $-0.63 | ||
| Q2 24 | — | $-2.57 | ||
| Q1 24 | — | $-0.11 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
